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a b s t r a c t
Japanese encephalitis virus (JEV) is a serious mosquito-borne ﬂavivirus that causes acute encephalitis in
humans and many animals, with a high fatality rate. RNA interference (RNAi) is an evolutionarily
conserved mechanism for the speciﬁc suppression of gene expression, which can be used as a reasonable
antiviral strategy. In this study, 10 shRNAs targeting different regions of the JEV genome were designed,
and their inhibition of viral replication in vitro and in vivo was determined. Treatment with these shRNAs
signiﬁcantly inhibited JEV replication in BHK-21 and SK-N-SH cells. An immunohistochemical analysis of
suckling mice showed that brain sections pretreated with pGP-JE-1, pGP-JE-2 or pGP-JE-3 lacked viral
particles. The survival of BALB/c mice challenged with 20 LD50 of the JEV NJ2008 strain at 24 h post-
injection or simultaneously with pGP-JE-2 was 83.3% and 66.7%, respectively. The results demonstrated
that the efﬁciency of gene silencing and virus inhibition varied between shRNAs to different target genes
and sites. Meanwhile, the shRNA-mediated antiviral effect was dose- and time-dependent, including
prophylactic and therapeutic effect on virus infection both in vitro and in vivo. The whole results indicate
that these shRNAs can inhibit JEV infection sufﬁciently in vitro and in vivo and might be a potential new
tool for controlling JEV infection.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Japanese encephalitis virus (JEV) belongs to the Flavivirus genus
of the Flaviviridae family and causes infection of the central nervous
system in humans and stillbirths in swine (Burke et al., 2001). JEV has
a zoonotic transmission cycle between birds and mosquitoes, with
swine serving as intermediated ampliﬁer hosts and the virus can
spread from swine to humans via mosquito bites (van de Hurk et al.,
2009; Weaver and Barrett, 2004). According to the latest report of
the World Health Organization, Japanese encephalitis (JE) is endemic
in 24 Asian and Oceanian countries, with an estimated 68,000 JE
cases annually. More than 3 billion people live in JE-endemic
countries (Campbell et al., 2011; Mackenzie and Williams, 2009).
Furthermore, JE infections are lethal in about 25–30% of cases, mostly
in infants, and lead to permanent sequelae in about 50% of cases
(Ghosh and Basu, 2009; Flohic et al., 2013). JE is thus a continuing
public health threat. Accordingly, the development of new treat-
ments and antiviral drugs against JEV are expected.
JEV contains a single-stranded, plus-sense RNA genome of
approximately 11 kb. It consists of a single open reading frame
that codes for a large polyprotein of 3432 amino acids that is co-
and post-translationally cleaved into three structural proteins
(capsid, C; premembrane, prM; and envelop, E) and seven non-
structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5)
(Lindenbach et al., 2007; Sumiyoshi et al., 1987).
RNAi is a post-transcriptional mechanism of gene silencing
ﬁrst described as an innate response to viral infections in plants
and subsequently in all higher-order eukaryotes (Bosher and
Labouesse, 2000; Hannon, 2002). In this process, dsRNA is cleaved
into siRNAs of 21–25 nt by the RNase III-like enzyme dicer. These
siRNAs are associated with a multiprotein complex known as the
RNA-induced silencing complex (RISC), and they ultimately
degrade the homologous mRNA and prevent protein translation
(Dykxhoorn et al., 2003). A major advance in the ﬁeld occurred
with the discovery that synthetic short dsRNAs resembling the
dicer-processed product could mediate speciﬁc gene silencing in
mammalian cells without evoking an interferon (IFN) response
(Dahlgren et al., 2006; Elbashir et al., 2001). These ﬁndings have
led to the emergence of a new ﬁeld of drug discovery with RNAi
therapeutics that target a wide variety of human diseases, ranging
from cancer to metabolic diseases and viral infections (de Fougerolles
et al., 2007). Recent studies have demonstrated the efﬁcacy of RNAi-
induced inhibition of viruses in vitro and in vivo, including hepatitis
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2014.01.025
0042-6822 & 2014 Elsevier Inc. All rights reserved.
n Corresponding author. Fax: þ86 25 84396335.
E-mail address: shentingnau@hotmail.com (T. Shen).
Virology 454-455 (2014) 48–59
C virus (Arbuthnot et al., 2007; Pan et al., 2012; Suhy et al., 2012),
hepatitis B virus (Pichard et al., 2012; Wang et al., 2013; Wooddell
et al., 2013), West Nile virus (Anthony et al., 2009; Krishnan et al.,
2008; Schnettler et al., 2012), and inﬂuenza virus (Langlois et al.,
2013; Meliopoulos et al., 2012).
In this study, 10 different regions of the major JEV genome
containing the C, E, NS1, NS3, NS4b and NS5 genes were selected
as the silencing targets. Ten corresponding shRNA-expressing
plasmids were constructed. Using a shRNA, we established deﬁ-
nitive proof that the replication of JEV can be inhibited effectively
in BHK-21 and SK-N-SH cells. Furthermore, we ﬁrst analyzed and
compared the antiviral activity among the shRNAs targeting JEV
various genes. Moreover, we explored the feasibility of shRNA-
based intervention to suppress lethal JE in mice. Our results
provide novel insights into the inhibition of JEV replication in
cells and animals, and highlight the antiviral potential of RNAi.
Results
Confocal ﬂuorescence analysis of shRNA-induced inhibition of JEV in
BHK-21 cells
To substantiate the inhibitory levels of different shRNAs intui-
tively, an indirect immunoﬂuorescence assay was performed using
an anti-JEV-E protein monoclonal antibody and the Alexa Fluors
594 s second antibody at 24 h post-challenge (hpc). JEV was stained
with red ﬂuorescence and nucleus was stained with 40',6-diamidino-
2-phenylindole (DAPI). The results showed that all ten shRNAs
suppressed JEV replication signiﬁcantly compared with pGP-NC.
Notably, the red ﬂuorescence was barely detectable in the cells
treated with pGP-JE-2, pGP-JE-1, pGP-JE-3, pGP-JNS4b-1. In conclu-
sion, the ten shRNAs we designed played a role of down-regulation
in JEV replication in BHK-21 cells successfully (Fig. 1).
Fig. 1. shRNA-induced inhibition of JEV replication was detected by indirect immunoﬂuorescence. JEV was stained with red ﬂuorescence and nucleus was stained with DAPI.
Stained cells were observed by confocal laser scanning microscopy. Magniﬁcation, 200 . Data are from a representative experiment.
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shRNAs reduce JEV titer in BHK-21 cells
On one hand, the results of TCID50 showed that the shRNA-
mediated antiviral effect was dose-dependent. The inhibitory efﬁcacy
reduced slightly with the increased injection of JEV (Fig. 2A). The
high concentrations of shRNAs inhibited JEV replication more effec-
tively than low concentrations of shRNAs (Fig. 2B).
On the other hand, the results of TCID50 showed that the shRNA-
mediated antiviral effect was time-dependent. No matter whether
shRNAs transfection prior or posterior to JEV infection, the antiviral
effect was slightly reduced with increasing hours of observation,
however shRNAs inhibited JEV replication effectively and stably in
BHK-21 cells during at least 72 h post-challenge/transfection (Fig. 2C
and E). Remarkably, the JEV titer was reduced about 104-fold in
cells pretreated with pGP-JE-2, pGP-JE-1 or pGP-JE-3, compared with
pGP-NC. The JEV titer of the samples pretreated with pGP-JNS4b-1,
pGP-JNS3, pGP-JC or pGP-JNS1-1 was reduced by 103-fold compared
with pGP-NC. The JEV titer of the samples treated with pGP-JNS1-2,
Fig. 1. (continued)
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pGP-JNS4b-2 or pGP-JNS5 was decreased 10 times compared with the
negative control (Fig. 2C). Furthermore, even if virus infection 6 h prior
to shRNAs transfection, the TCID50 values were reduced signiﬁcantly
compared with pGP-NC (Fig. 2D).
shRNAs inhibit JEV replication at the mRNA level
To determine the relative expression of JEV mRNA by treatment
with the shRNAs, total RNA was extracted from BHK-21 and SK-N-
SH cells at 24, 48 and 72 hpc for quantitative RT-PCR analysis.
Primers targeting the JEV 3'-untranslated region, GAPDH (as the
internal reference for BHK-21 cells) and beta-actin (as the internal
reference for SK-N-SH cells) were used. The data showed that all
ten shRNAs suppressed the expression of JEV mRNA notably in
cells compared with pGP-NC group, however the inhibitory effect
varied among these shRNAs. In BHK-21 cells, the shRNAs inhibited
JEV replication by 450% except for pGP-JNS1-2 and pGP-JNS5,
especially pGP-JE-1, pGP-JE-2, pGP-JE-3 and pGP-JNS4b-1 sup-
pressed JEV outstandingly all by 490% (Fig. 3A). Meanwhile, we
determined the antiviral activity of the shRNAs in human neuro-
blast cells. The relative expression of JEV 3'-untranslated mRNA to
beta-actin mRNA was o50% in SK-N-SH cells treated with pGP-JC,
pGP-JE-1, pGP-JE-2, pGP-JE-3, pGP-JNS-1, pGP-JNS3 or pGP-JNS4b-
1. In particular, more than 90% of viral mRNA expression was
Fig. 2. Decrease of virus yield in BHK-21 cells transfected with shRNAs. (A) Cells were pretransfected with 0.8 μg shRNA, then challenged with JEV at MOIs of 0.05, 0.5 and 1.
Culture supernatants were collected at 24 hpc. (B) Cells were pretransfected with 0.4, 0.8 and 1.2 μg shRNA, then challenged with JEV at 0.1 MOI. Culture supernatants
were collected at 24 hpc. (C) Cells were pretransfected with 0.8 μg shRNA, then challenged with JEV at 0.1 MOI. Culture supernatants were collected at 24/48/72 hpc.
(D) Cells were challenged with 0.1 MOI of JEV for 1.5/3/6 h, then transfected with 0.8 μg shRNA. Culture supernatants were collected at 24 hpt. (E) Cells were challenged with
0.1 MOI of JEV for 1.5 h, then transfected with 0.8 μg shRNA. Culture supernatants were collected at 24/48/72 hpt. All the culture supernatants were measured by TCID50
(Po0.05).
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powerfully silenced by pGP-JE-1, pGP-JE-2 and pGP-JE-3 in SK-N-
SH cells (Fig. 3A). Besides, the data indicated that the level of JEV
transcripts were reduced stably in both cell types at intervals post-
challenge, in other words, the shRNAs can inhibit JEV replication
effectively through at least 72 hpc in BHK-21 and SK-N-SH cells.
To further research the inhibitory effect–time relationship, cells
were infected with JEV for 1.5, 3 and 6 h, and then viral RNA was
extracted at 72 h post-transfection (hpt) from BHK-21 and SK-N-
SH cells. The inhibitory effect of pGP-JE-1, pGP-JE-2 and pGP-JE-3
was still 485% in both cell types (Fig. 3B). It demonstrates that
the RNAi-mediated inhibition of virus remains effectively even
after an infection has been established in cells. However, the
overall therapeutic effect of shRNAs was relatively weaker than
their prophylactic effect against viral replication. The inhibition of
JEV replication in BHK-21 and SK-N-SH cells is time dependent by
shRNAs. Moreover, due to the outstanding antiviral performance of
shRNAs in human nerve cells (SK-N-SH cells), the clinical
application of shRNA-mediated RNAi is potential to suppress
JEV-induced encephalitis.
Besides, the high concentrations of shRNAs suppressed JEV
mRNA expression more effectively than low concentrations of
shRNAs (Fig. 3C).
Assay of shRNA inhibition of JEV replication in BHK-21 cells by ﬂow
cytometry
The inhibitory effect of the various shRNAs on the expression of
the E protein were quantitatively determined by ﬂow cytometry in
BHK-21 cells at 48 hpc. The extent of E protein down-regulation
was quantiﬁed by assessing the numbers of FITC-positive cells. The
percentage of FITC-positive cells was o50% except in the pGP-
JNS5 treated wells (58.7%). The inhibitory efﬁciency of pGP-JE-2,
pGP-JE-1, pGP-JE-3, pGP-JNS4b-1, pGP-JC and pGP-JNS3 was 97.4%,
92.3%, 87.7%, 81.5%, 79.4% and 72.5%, respectively, relative to the
Fig. 3. Quantitative RT-PCR analysis of the inhibition efﬁciency of ten shRNAs to JEV. (A) JEV RNA extracted from BHK-21 or SK-N-SH cells pretreated with different shRNAs at
intervals post-challenge (24/48/72 h), GAPDH as the internal reference for BHK-21, beta-actin as the internal reference for SK-N-SH cells. (B) JEV RNA were extracted from
BHK-21 or SK-N-SH cells at 72 hpt, which were ﬁrst challenged with JEV for 1.5, 3 and 6 h followed with transfection of each shRNA. (C) BHK-21 cells were pretransfected
with different concentrations of shRNAs. At 72 hpc, relative expression of JEV mRNA was determined (Po0.05).
T. Shen et al. / Virology 454-455 (2014) 48–5952
negative control pGP-NC (Fig. 4). Apparently, the expression of JEV
E protein was strongly reduced by the transfection with these
6 shRNAs above, whereas the transfection with the remaining
4 shRNAs resulted in a somewhat less robust reduction.
shRNAs inhibit JEV replication at the protein level by western blotting
The E protein is one of the most important JEV proteins and
has an approximate molecular mass of 54 kDa. To further analyze
the inhibitory effect of shRNAs at protein level, BHK-21 cells were
assayed by western blotting at 48 hpc. All the BHK-21 cells expressed
the 42-kDa β-actin protein detected by an anti-beta-actin mAb, and
only the infected cells expressed the expected 54-kDa E protein as
detected by an anti-JEV-E mAb. No signiﬁcant band was seen in the
cells transfected with pGP-JE-2. Only a faint band of the E proteinwas
observed in the transfections with pGP-JE-1, pGP-JE-3, pGP-JNS4b-1
and pGP-JC compared with the pGP-NC transfection. The pGP-NS3,
pGP-JNS1-1, pGP-JNS4b-2, pGP-JNS1-2 and pGP-JNS5 bands were
thinner and lighter than pGP-NC band. No E protein was observed in
the normal cells (Mock) (Fig. 5). These results indicated that 3 shRNAs
targeting the E gene suppressed the translation of the JEV E protein
especially well.
Cytokines analysis in BHK-21 and SK-N-SH cells with shRNAs
simulation
Although RNAi strategies are reliant on a high degree of speciﬁ-
city, little attention has been given to the potential non-speciﬁc
effects that might be induced. It has been reported that siRNAs can
stimulate the IFN pathway under certain circumstances (Malathi
et al., 2007; Sledz et al., 2003). Therefore, we examined whether the
shRNAs were able to induce IFN-β production in uninfected BHK-21
and SK-N-SH cells. Supernatants were collected at 24 hpt from
shRNA-treated BHK-21 or SK-N-SH cells, and analyzed by ELISA for
IFN-β induction. The results showed that the supernatants revealed
no apparent differences at the level of IFN-β between shRNA-treated
and nontransfected cells (mock) in two type cells, whereas poly(I-C)
induced a strong IFN response (Fig. 6A).
Furthermore, to substantiate the potential of clinical application
of shRNA, we determined whether the simulation of shRNA were
possible to induce some side-effects in SK-N-SH cells, such as
inﬂammatory response. Supernatants were collected at 24 hpt from
shRNA-treated SK-N-SH cells, and analyzed by ELISA for TNF-α
induction. The results showed that the level of TNF-α in shRNA-
treated cells remained stable, relative to nontransfected cells (mock),
whereas LPS induced TNF-α secretion to a high degree (Fig. 6B).
Thus, in our study, the antiviral effect of shRNA was not due to
the induction of an IFN response. shRNA effectively inhibits JEV
replication by RNAi-mediated degradation of viral RNA in BHK-21
and SK-N-SH cells.
shRNAs protect the suckling mice against JEV infection
Brain sections from suckling mice challenged with JEV were
examined for pathological changes 4 days post-challenge (dpc).
Brains from the mice of virus control and negative control (pGP-
NC) showed the typical histopathological features of a diffuse,
disseminated viral encephalitis with hemorrhage, extensive
Fig. 4. Flow cytometry analysis of JEV positive cells. The percent of JEV positive
cells in BHK-21 cells were measured by assessing the number of FITC-positive cells.
Data are from a representative experiment.
Fig. 5. Western blot analysis of gene silencing at the protein level. Cells were
harvested and separate by 12% SDS-PAGE. Beta-actin protein served as the loading
control: reduction of JEV-E protein levels in BHK-21 cells. Mock is non-infected cell
control. Data are from a representative experiment. Fig. 6. (A) Absence of IFN-β induction in BHK-21 and SK-N-SH cells cultures following
shRNA transfection. IFN-β production levels were determined by ELISA for super-
natants of nontransfected cells (mock) and cells transfectedwith each shRNA (100 nM)
or with poly(I-C) (0.5 μg/ml). Samples differ signiﬁcantly from poly(I-C) (Po0.05).
(B) Absence of TNF-α induction in SK-N-SH cells cultures following shRNA transfec-
tion. TNF-α production levels were determined by ELISA for supernatants of
nontransfected cells (mock) and cells transfected with each shRNA (100 nM) or with
LPS (1 μg/ml). Samples differ signiﬁcantly from LPS (Po0.05).
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perivascular leukocyte inﬁltration, and neuronal apoptosis. Many
virus particles were present in the brain sections, staining dark
brown. The virus particles were barely detectable in the brains
sections from the mice pretreated with pGP-JE-1, pGP-JE-2, pGP-JE-
3 or pGP-JNS4b-1, similar to the mock control (PBS). The numbers of
virus particles in the brain sections from the mice pretreated with
pGP-JC, pGP-JNS3, pGP-JNS1-1, pGP-JNS1-2, pGP-JNS4b-2 and pGP-
JNS5 was signiﬁcantly lower than in the virus control group (Fig. 7).
Moreover, the brain tissue were measured by plaque assays on
BHK-21 on 4 dpc, for quantiﬁcation of JEV in brains of suckling
mice. The results showed that brain homogenates from the virus
control and negative control mice revealed extremely high levels
of viral replication, whereas the homogenates from the shRNA-
treated mice remained at a low level of JEV. Remarkably, the JEV
titer was reduced about 104-fold in the mice treated with pGP-JE-
2, pGP-JE-1 or pGP-JE-3, compared with the virus control and
pGP-JC pGP-JE-1 pGP-JE-2
pGP-JE-3 pGP-JNS1-1 pGP-JNS1-2
pGP-JNS3 pGP-JNS4b-1 pGP-JNS4b-2
pGP-JNS5 Virus control Mock
pGP-NC
Fig. 7. Immunohistochemistry analysis of brain sections from shRNAs-treated suckling mice. The control groups were negative control (pGP-NC), virus control (JEV) and mock
(PBS). The arrows in ﬁgure staining dark brown are the sites of virus particles, which were stained with DAB. Magniﬁcation, 400 . Data are from a representative experiment.
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negative control. And the treatment of pGP-NS3, pGP-NS4b-1 or
pGP-JC decreased the JEV replication in suckling mice to the
degree of 103-fold, relative to the virus control and negative
control (Fig. 8). Thus, shRNAs depressed the viral load of JEV in
brain of mice signiﬁcantly.
shRNAs protect BALB/c mice against JEV challenge
We evaluated the potential of the shRNAs to protect mice
against a lethal dose of a JEV virulent strain challenge. BALB/c mice
were injected i.e. with each different shRNAs including pGP-NC.
Subsequently, the mice were challenged with 20 LD50 of NJ2008 at
the same site 24 hpt and were observed for 15 days. Four shRNAs
targeting the structure domains of the JEV genome protected 50%
of the mice; notably, 83.3% of the mice pretreated with pGP-JE1 or
pGP-JE2 survived (Fig. 9A). The survival of the mice treated with
pGP-JNS1-1, pGP-JNS3 or pGP-JNS4b-1 was, respectively, 50%, 50%
and 66.7% at 15 days post-challenge (Fig. 9B). Furthermore, we
tested the ability of the shRNAs to protect against increasing doses
of JEV (100 LD50). Up to 50% of the mice that were pretreated with
pGP-JE-1, pGP-JE-2, pGP-JE-3 or pGP-JNS4b-1 survived to the end
of the observation period; notably, the prophylactic ability of the
three shRNAs targeted to the E gene resulted in a survival rate of
66.7% (Fig. 9C and D).
Moreover, we simultaneously challenged mice with 20 LD50 of
NJ2008 and injected them with shRNAs. pGP-JE-1, pGP-JE-2 or pGP-
JE-3 all protected 66.7% of the mice to survive (Fig. 9E); pGP-JNS3 or
pGP-JNS4b-1 conferred 50% protection (Fig. 9F). When the mice were
challenged with 100 LD50 of NJ2008, the survival rate was 450% in
those treated with pGP-JE-1 or pGP-JE-2 through 15 dpc (Fig. 9G).
The prophylactic effect of the six shRNAs targeting the JEV
nonstructural domains was relatively weaker than that of the four
shRNAs targeting the JEV structural domains, especially the JEV E
gene. The survival of the mice treated with the same shRNA
challenged with 100 LD50 of NJ2008 decreased slightly compared
Fig. 8. The viral load in the brain tissues from the suckling mice treated with
shRNA were plaque-titrated on BHK-21 cell monolayers. Each symbol represents an
individual mouse. The horizontal line corresponds to the median viral titers of the
group (Po0.05).
Table 1
RNAi target genes and sequences.
Target gene Site Target sequences
C 423-441 5'-GGCTCAATCATGTGGCTCG-3'a
E-1 1287-1305 5'-GGATGTGGACTTTTCGGGA-3'b
E-2 1555-1573 5'-GGAGTGGACTGAACACTGA-3'
E-3 1681-1699 5'-ACAGAGAACTCCTCATGGA-3'
NS1-1 2946-2964 5'-GACTTCGGCTTTGGCATCA-3'c
NS1-2 4112-4130 5'-GAAAGGAGCTGTACTCTTG-3'
NS3 6085-6103 5'-AGATCATGTTAGACAACAT-3'
NS4b-1 7352-7370 5'-GAATGCCGTTGTTGACGGA-3'
NS4b-2 8010-8028 5'-GAACCGATGCTCATGCAGA-3'
NS5 10732-10750 5'-GGACTAGAGGTTAGAGGAG-3'
NC Nonsense 5'-GTTCTCCGAACGTGTCACGT-3'
A nonsense sequence was designed as the negative control (NC), which of the 56-nt
oligonucleotide shRNA was 5'-CACCGTTCTCCGAACGTGTCACGTCAAGAGATTACG
TGACACGTTCGGAGAATTTTTTG-3'(sense).
a Murakami et al. (2005).
b Kumar et al. (2006).
c Liu et al. (2006).
Fig. 9. shRNAs protect BALB/c mice from JEV challenge. (A and C) Survival rate of mice pre-injected i.c. with pGP-JC/pGP-JE-1/pGP-JE-2/pGP-JE3 were challenged with 20/100
LD50 JEV. (B and D) Survival rate of mice pre-injected i.c. with pGP-JNS1-1/pGP-JNS1-2/pGP-JNS3 /pGP-JNS4b-1/pGP-JNS4b-2/pGP-JNS5 were challenged with 20/100 LD50
JEV. (E and G) Survival rate of mice were injected i.c. with pGP-JC/pGP-JE-1/pGP-JE-2/pGP-JE3 and 20/100 LD50 JEV simultaneous. (F and H) Survival rate of mice were injected
i.c. with pGP-JNS1-1/pGP-JNS1-2 /pGP-JNS3/pGP-JNS4b-1/pGP-JNS4b-2/pGP-JNS5 and 20/100 LD50 JEV simultaneous.
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with those challenged with 20 LD50 of NJ2008. Remarkably,
the inhibitory efﬁciency of RNAi was dose-dependent to a point;
however, the protection failed to last stably when the titer or
quantity of the virus challenge reached a threshold. Similarly, the
inhibitory efﬁciency of RNAi was time-dependent; the survival of
the mice that were treated with the shRNAs ﬁrst was relatively
higher than in those that were simultaneously challenged with the
virus and the shRNAs.
Discussion
JE is an important public health problem worldwide. An esti-
mated 3 billion people are at risk, and JE has recently spread to new
territories (Campbell et al., 2011). Vaccine inoculation is the major
strategy to control JE. But inoculation failure and emerging infection
often leaded to diseases. Until now, no speciﬁc remedy for JEV is
obtained. Our study is focus on the treating of JEV infection. Although
some RNAi sequences were reported in JEV inhibition (Kumar et al.,
2006; Liu et al., 2006; Murakami et al., 2005; Qi et al., 2008), the
overall screening of RNAi in vitro and in vivo is not determined. In this
study, we designed 10 shRNAs targeting various JEV genes to assay
the antiviral effect in BHK-21 and SK-N-SH cells. Furthermore, we
determined the antiviral effect of shRNAs in mouse.
JEV genome encoded three structural proteins (C, M and E) and
seven nonstructural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b
and NS5) (Lindenbach et al., 2007). We designed 10 RNAi
sequences target these genes, and all of these showed markedly
antiviral activity in vitro and in vivo. In contrast, shRNA targeting
structural genes showed higher antiviral activity than nonstruc-
tural genes. On one hand, nonstructural proteins are enzymes for
viral replication and hydrolysis. These enzymes are important to
virus replication, but little enzymes are needed in this process
(Bollati et al., 2010). On the other hand, nonstructural proteins
showed inhibitory activity against host immunity respond. NS5
was reported as an inhibitor of interferon pathway, and other NS
proteins in West Nile virus (WNV) or Dengue virus (DENV) also
showed inhibitory activity against immunity respond (Mazzon
et al., 2009). To sum up, the results inferred that shRNA targeting
nonstructural gene reduced the amount of NS proteins and
released the host antiviral immunity system, but the viral enzyme
activity is not affected (Bollati et al., 2010).
Structural genes inﬂuence the adsorption, entry, assemble and
release of JEV. Antiviral results indicated shRNA targeting struc-
tural genes is the best way to inhibit virus. The highest antiviral
activity was determined by shRNAs targeting E gene, this results
infer the important role of E protein in JEV replication. E protein is
an envelope glycoprotein which determines the virus adsorption,
entry, assemble and other course. It is the key protein in JEV life
(Luca et al., 2012). In addition to E gene, shRNA target C and NS4b-
1 gene showed high antiviral activity too. C protein inﬂuences the
nucleic localization of JEV (Pan et al., 2009) and NS4b inﬂuence the
replication and hydrolysis of JEV. These two proteins are important
to JEV infection, and the results showed that JEV replication was
reduced signiﬁcantly after C and NS4b gene silencing.
Human neuroblastoma cells showed the same characteristics
like nerve cells, we used SK-N-SH cells as the nerve cells infection
model in this study. In SK-N-SH cells, shRNAs showed high
antiviral activity against JEV. In contrast to BHK-21 cells, shRNAs
targeting E, NS4b-1 and C also indicated the robust antiviral effect.
Inﬂammation is an important feature of encephalitis virus infec-
tion and excessive inﬂammation respond would induce brain
injuries and sequelae in JEV patients. In our study, TNF-α levels
were detected in shRNA-transfected SK-N-SH cells. Results indi-
cated that there are no TNF-α induction by shRNA-expressing
plasmid. Thus, shRNA-expressing plasmid is a safe antiviral agent
in encephalitis treatment. Besides, IFN-β was detected in this
study. Results indicated that shRNA-expressing plasmid is a steady
antiviral agent without evoking interferon response. These results
also inferred that our shRNAs inhibited JEV replication directly.
In vivo, the results of immunohistochemistry showed that brains
sections from suckling mice pretreated with pGP-JE-1, pGP-JE-2, pGP-
JE-3 or pGP-JNS4b-1 lacked virus particles, similar to the Mock
controls. The number of virus particles in brain sections from mice
pretreated with pGP-JC, pGP-JNS3, pGP-JNS1-1, pGP-JNS1-2, pGP-
JNS4b-2 and pGP-JNS5 was signiﬁcantly lower than that in the virus
control and negative control. The prophylactic effect of the shRNAs
targeting JEV structural domains was generally stronger than that of
the shRNAs targeting JEV nonstructural domains in vivo. These results
strongly indicated that shRNA is an potential antiviral agent for the
excellent antiviral activity in vivo.
The overall survival rate by the prophylactic effect of shRNAs
was relatively higher than their therapeutic effect. Furthermore, the
protection rate of shRNA exists the dose-dependence, as the survival
rates of mice challenged with 100 LD50 JEV lower than those with 20
LD50 JEV. And from all the results in vivo, shRNAs targeting E gene
have the best antiviral effect. These results in vivo demonstrated that
shRNA-expressing plasmid could be used as an antiviral drug in vivo.
In summary, we constructed 10 shRNA plasmids targeting the
genome of JEV, which could inhibit JEV replication in vitro and
in vivo to various degrees. shRNA target E, NS4b and C gene
showed the inhibition outstandingly. It is possible that RNAi will
be able to be used as inhibitors of ﬂavivirus replication. However,
for the development of a potential and useful antiviral drug,
further clinical experiments using RNAi are necessary.
Materials and methods
Cells and virus
Baby hamster kidney cells (BHK-21) and human neuroblastoma
cell line (SK-N-SH) were maintained at 37 1C in an atmosphere of
5% CO2 in Dulbecco's modiﬁed Eagle's medium (Gibco) containing
10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin,
and 100 μg/ml streptomycin. JEV strain NJ2008 (GQ918133) was
used for viral challenge.
Animals
Suckling mice and female BALB/c mice aged 4–6 weeks (purchased
from Model Animal Research Center of Nanjing University) were used
in vivo experiments. All mice were maintained in sterile cages in
speciﬁc-pathogen-free environments. All animal experiments were
performed in accordance with the Animal Ethics and Experimental
Committee Guidelines of Nanjing Agricultural University.
Construction of shRNA expressing plasmids
Ten target sequences in the coding region of C, M, E, NS1, NS3,
NS4b and NS5 genes were selected according to a web-based
siRNA design tool (siRNA target-ﬁnder, http://www.ambion.com/)
(Table 1). The speciﬁcity of these sequences was veriﬁed by a
BLAST search. A nonsense siRNA sequence was also designed as
the negative control. The target sequences were used to design
two complementary siRNA template oligonucleotides. All oligonu-
cleotides were synthesized by Genepharma. After annealing the
oligonucleotides, they were inserted into the BamHI and BbsI sites
of the siRNA expression vector pGPU6/Neo (abbreviation: pGP;
Shanghai Genepharma., Ltd.). These recombinant plasmids trans-
formed into Escherichia coli DH5α, then, were extracted, digested
and sequenced ( by BGI-Shenzhen Corporation) to identify the
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positive plasmids, which were named pGP-JC, pGP-JE-1, pGP-
JE-2, pGP-JE-3, pGP-JNS1-1, pGP-JNS1-2, pGP-JNS3, pGP-JNS4b-1,
pGP-JNS4b-2, pGP-JNS5 and pGP-NC. The recombinant plasmids
were puriﬁed with the QIAGEN Plasmid Puriﬁcation Max Kits
(QIAGEN) and quantiﬁed by the Eppendorf Biophotometer.
Cell transfection and viral infection
Growth and titration of JEV were conducted using cultured
BHK-21 cells, and TCID50 values were calculated using the Reed–
Muench method. Viral suspensions of 106–107 TCID50/ml were
used for the experiments. BHK-21 cells were plated in 24 well
plates at 2105 cells per well in antibiotic-free medium overnight.
When the cell layer reached 70% conﬂuence, 0.8 μg of 10 shRNAs
and negative control (pGP-NC) were individually transfected into
cells in 100 μl OPTIMEM medium (Invitrogen) mixed with Lipo-
fectamine 2000 (Invitrogen). Non-transfected BHK-21 cells were
used as a blank control (Mock). After 6 h of shRNA treatment, the
culture medium was immediately replaced with fresh medium
containing 2% FBS. Twenty-four hours post-transfection, the cells
were infected with the JEV strain NJ2008 at 0.1 MOI. The cultures
were incubated for 1.5 h, and then the culture medium was
replaced with fresh medium containing 2% FBS. SK-N-SH cells
were treated the same with BHK-21 cells as described above.
Moreover, to normalize the transfection efﬁciency of shRNAs,
the relative expression of neomycin resistance gene of pGPU6/Neo
was determined by quantitative RT-PCR. The speciﬁc primers were
as follows: forward primer: 5'-TGATATTGCTGAAGAACT-3'; reverse
primer: 5'-TGATATTGCTGAAGAA CT-3'. GAPDH and beta-actin
served as an internal reference for BHK-21 and SK-N-SH cells.
The results were in Supplementary data (Fig. 1S).
Confocal ﬂuorescence analysis
BHK-21 cells were pretransfected and infected as described
above. 24 hpc, the infected cells were ﬁxed in 80% ice-cold acetone
at 20 1C for 10 min and blocked in 2% BSA at room temperature
for 2 h. After washing, the cells were incubated with a mouse
monoclonal antibody against the E protein of JEV (kindly provided
by Pro. Shengbo Cao, Huazhong Agricultural University, Wuhan,
China) and the Alexa Fluors 594 s antibody (Invitrogen). The cells
were stained with 40',6-diamidino-2-phenylindole (DAPI) for
10 min. After washing, the cells were examined and photographed
with confocal ﬂuorescence microscopy (Nikon).
TCID50 measurement
BHK-21 cells were transfected with different concentrations
(0.4, 0.8 and 1.2 μg) of each shRNA 24 h before JEV infection at
various MOIs (0.05, 0.5 and 1). Supernatant ﬂuids were harvested
at various times (24, 48 and 72 h) post-challenge. Serial 10-fold
dilutions were made from the supernatant stocks, and 100 μl
samples of each dilution were added to duplicated wells of a 96-
well plate containing a conﬂuent monolayer of BHK-21 cells. Seven
days were allowed for the appearance of cytopathology. The
dilution causing cytopathology in half of the cultures (the median
tissue culture infective dose, TCID50) was then calculated by the
Reed and Muench method. In addition, cells were infected with
JEV for 1.5, 3 and 6 h, then transfected with shRNAs. At 24, 48 and
72 hpt, supernatant ﬂuids were measured by TCID50.
Quantitative RT-PCR
To analyze the inhibitory effect at mRNA level, SYBR Green I
real-time RT-PCR was performed using speciﬁc primers based on
the sequence of the JEV 3' noncoding region as follows: forward
primer: 5'-CCC TCA GAA CCG TCT CGG AA-3', reverse primer: 5'-
CTA TTC CCA GGT GTC AAT ATG CTG-3'. GAPDH served as an
internal reference for BHK-21 cells and the speciﬁc primers were
as follows: forward primer: 5'-CCC CAA TGT GTC CGT CGT G-3';
reverse primer: 5'-GCC TGC TTC ACC ACC TTC T-3'. beta-actin
served as an internal reference for SK-N-SH cells and the speciﬁc
primers were as follows: forward primer: 5'-GGA CTT CGA GCA
AGA GAT GG-3'; reverse primer: 5'-AGC ACT GTG TTG GCG TAC AG-
3'. At 24/48/72 hpc, the cells pretreated with the shRNAs with
different concentrations in 24-well plates were lysed by TRIzol
Reagent (Invitrogen); the cells challenged with JEV for 1.5/3/6 h
were transfected with shRNAs and lysed by TRIzol Reagent
(Invitrogen) at 72 hpt. Total RNA was isolated according to the
manufacturer's instructions. Reverse transcription was carried out
by using Moloney murine leukemia virus reverse transcriptase
(Takara) in a 10 μl reaction mixture containing 3 μl RNA, according
to the manufacturer's recommendation. Ampliﬁcation was carried
out in a 50-μl reaction volume containing 4 μl cDNA, 25 μl Power
SYBR Green PCR Master Mix (Takara), 1 μl ROX Reference Dye,
0.5 μl of each primer and 19 μl ddH2O. The reaction protocol was
95 1C for 30 s, followed by 40 cycles of 95 1C for 5 s and 60 1C for
31 s. Real-time RT-PCR was performed in an ABI PRISM 7300
sequence detection system and analyzed with ABI PRISM 7300SDS
software (Applied Biosystems). Cycle times of internal reference
that varied by 41.0 U in triplicate were discarded. Cycle times of
the target gene were averaged and normalized to the averaged
cycle time of GAPDH or β-actin accordingly.
Flow cytometry assay
BHK-21 cells were transfected and infected as describe above.
At 48 hpc the cells were washed gently in PBS, trypsinized, and
resuspended in PBS, and then incubated with anti-JEV-E protein
monoclonal antibody, followed by incubation with FITC–goat anti-
mouse IgG (Boster). The FITC-positive cells were evaluated by ﬂow
cytometry using the FACS Calibur Flow Cytometry System (BD
Biosciences), assisted by the Cell Engineering Center of Nanjing
Drum Tower Hospital.
Western blotting analysis
BHK-21 cells were transfected and infected as describe above.
At 48 hpc the cells were harvested from six-well plates, washed
twice with PBS, and boiled for 10 min after mixing with 5
loading buffer. Proteins were analyzed by 12% SDS-PAGE followed
by blotting onto two polyvinylidene diﬂuoride membranes, which
were then blocked in PBS containing 5% non-fat dry milk over-
night at 4 1C. One membrane was incubated with anti-JEV-E
protein monoclonal antibody and the other with anti-beta-actin
monoclonal antibody (Boster) for 2 h at room temperature. The
membranes were washed three times with PBS, followed by
incubation with peroxidase-conjugated goat anti-mouse antibody
or peroxidase-conjugated SPA (Staphylococal Protein A, Boster) for
2 h at room temperature. Membranes were washed three times
with TBS (100 mmol/L Tris HCl pH7.5, 150 mmol/L NaCl). The
proteins were visualized by enhanced chemiluminescence.
E protein and beta-actin served as the target protein and internal
protein reference, respectively.
ELISA for beta interferon (IFN-β) and alpha TNF (TNF-α) analysis
BHK-21 and SK-N-SH cells were seeded into 24-well plates 24 h
before transfection. Cells were transfected with each shRNA
(100 nM) or with poly(I-C) (0.5 μg/ml, Sigma), each of which was
mixed with Lipofectamine 2000 (Vigne et al., 2009). At 24 hpt, cell
culture supernatants were collected, and mouse/human IFN-β was
T. Shen et al. / Virology 454-455 (2014) 48–59 57
measured by Mouse or Human IFN-beta ELISA Kit (R&D Systems,
USA) following the manufacture's instructions.
SK-N-SH cells were transfected with each shRNA (100 nM)
mixed with Lipofectamine 2000. The positive control is the cells
treated with LPS (1 μg/ml, Sigma)for 6 h (Hoareau et al., 2010). At
24 hpt, cell culture supernatants were collected, and human TNF-α
was measured by Human TNF-alpha Quantikine ELISA Kit (R&D
Systems, USA) following the manufacture's instructions.
Immunohistochemistry analysis
Suckling mice were into 11 groups of four mice, and then
inoculated intracranially (i.c.) with 2 μg/g each different shRNA
every group, through the bregma (4 mm deep vertically into the
brain using a Hamilton syringe ﬁtted with a 30-gauge needle)
(Kumar et al., 2006). The mice were challenged with 5 LD50 JEV by
i.c. inoculation through the bregma at the same spot as described
above. After 96 h, brains were removed to 10% formalin, embedded
in parafﬁn, processed with anti-JEV-E protein monoclonal anti-
body, followed with peroxidase-conjugated SPA (Boster), and
ﬁnally, stained with DAB (3, 3N-Diaminobenzidine, Boster). Sec-
tions were stained with hematoxylin for pathological analysis. The
mice injected with pGP-NC were taken as the negative control. The
mice only challenged with PBS or JEV were taken as mock group
and virus control.
Plaque formation assay
Suckling mice were treated by each shRNA and challenged with
JEV the same as described above. On 4 dpc, the brain homogenates
were inoculated for 1.5 h on BHK-21 cells in six-well plates.
The culture ﬂuid was removed, 2 ml agarose was added per well
to overlay the BHK-21 cell monolayer, and culture was continued
at 37 1C in an atmosphere of 5% CO2 until there was a signiﬁcant
number of plaques in the cells. Cells were stained with crystal
violet for 15 min, and then the staining solution was discarded.
The number of plaques was counted. The control groups were
negative control, virus control and mock.
Immunoprotection test
BABL/c mice (6 per group) were inoculated i.c. with 5 μg/g each
various shRNA every group, through the bregma. After 24 h, the mice
were challenge with 20 or 100 LD50 of JEV, and then continuously
observed for survival over time with negative control (pGP-NC) and
mock groups. In addition, each group of six mice were treated i.c.
with 5 μg/g one shRNA and 20 or 100 LD50 JEV simultaneously, and
then observed for survival. Negative control (pGP-NC) and mock
group were treated and observed as described above.
Statistical analysis
All assays described herein were repeated at least three times,
and all of the measurements were made in triplicate. Mean
values7standard deviation (SD) were calculated using Microsoft
Excel. Statistical analysis was performed by one-way analysis of
variance, and values were considered signiﬁcant when po0,05.
Figures were created using the GraphPadTM Prism 5.0 software.
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